Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVTA
Invitae Corporation
NVTA
|
+$115M |
| 2 |
IGMS
IGM Biosciences
IGMS
|
+$63.5M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$47.4M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$26.6M |
| 5 |
UroGen Pharma
URGN
|
+$24.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$132M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$113M |
| 3 |
CPRX
Catalyst Pharmaceutical
CPRX
|
+$6.49M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$5.15M |
| 5 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$4.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.6% |
| 2 | Financials | 0.01% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AFMD
101
DELISTED
Affimed
AFMD
| $588K | ﹤0.01% |
20,000
| – | – |
|
|
EVFM
102
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $514K | ﹤0.01% |
+6,803
| New | +$522K |
|
|
VIRX
103
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $401K | ﹤0.01% |
15,905
| – | – |
|
104
Aquestive Therapeutics
AQST
$585M
| $317K | ﹤0.01% |
99,600
| – | – |
|
|
DVAX
105
DELISTED
Dynavax Technologies
DVAX
| $268K | ﹤0.01% |
75,000
| – | – |
|
|
TRIL
106
DELISTED
Trillium Therapeutics Inc.
TRIL
| $155K | ﹤0.01% |
505,262
| – | – |
|
|
AIXC
107
AIxCrypto Holdings Inc
AIXC
$22.7M
| $87K | ﹤0.01% |
22
| – | – |
|
|
RNTX
108
Rein Therapeutics
RNTX
$70.6M
| – | – |
-102,000
| Closed | -$1.47M |
|
|
ARRY
109
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-2,848,567
| Closed | -$132M |
|
Similar funds
Julian Baker's Q3 2019 Portfolio in Review
As of Q3 2019, Julian Baker held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.
Julian Baker's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Technology.
- Julian Baker's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
- Julian Baker added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
- Julian Baker's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
- Julian Baker fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
- Julian Baker's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
- Julian Baker opened 8 new positions and closed 2 in Q3 2019.
- Julian Baker's portfolio value fell 0.1% quarter-over-quarter to $14.7B.
Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.